We support CNS clinical trials by analyzing medical images from MRI and PET/SPECT scans as well as digital biomarkers. The output of these analyses allows us to effectively support clinical trial inclusion criteria, monitor patient safety and assess the clinical efficacy of drugs.
Since our inception we have pioneered AI-powered segmentation technologies, enabling volumes in the brain to be automatically measured and quantified. This minimizes the need for labor-intensive manual segmentations, creating valuable efficiencies in CNS trials.
Our pioneering use of deep learning for brain segmentation in clinical trials saw us rewarded with the ‘Greatest Innovation’ accolade in Dun & Bradstreet’s Accelerate50 2021.
We offer an extensive range of clinical trial imaging analysis tools including radiological reads, structural and advanced MRI, and PET and SPECT analysis. This enables us to support your patient stratification and clinical trial enrichment as well as conduct eligibility, safety, and efficacy assessments.
We combine the best wearable technology with our digital platforms and scientific and regulatory expertise. We work with CNS healthcare clients around the world to discover and clinically validate new digital biomarkers for deployment in clinical trials.
In neuroscience, AI has applications across the entire spectrum of understanding and treating neurodegenerative diseases. AI technology can be applied from the early stages of clinical research to select the most promising drug candidates, all the way through to late stage clinical development programmes to interpret complex patient data and even support new models of care in the community.
Our TrialTracker imaging platform for clinical trials is GCP and 21 CFR Part 11 compliant, providing everything you need to manage the complex imaging workflow of CNS clinical trials.
Our Assessa platform is a clinical decision support tool for patient selection and post-marketing surveillance. The secure digital platform enables the remote transfer of clinical and imaging data to provide central expert and automated review and analysis.